TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
Copenhagen - 25 June, 2009 - Pursuant to the Danish Securities Trading Act,
Section 28a TopoTarget A/S (OMX: TOPO) is obliged to report on transactions by
members of its board of directors, senior management and their related parties
in shares issued by TopoTarget A/S and related securities.
Name AntiAnthra ApS, a company owned by CED of TopoTarget A/S,
Reason Peter Buhl Jensen, Chief Scientific Officer Maxwell
Sehested and a third party
Issuer TopoTarget A/S
ISIN DK0060003556
Transaction Purchase of TopoTarget shares
Trade date 24 June 2009
Market NASDAQ OMX Copenhagen A/S
Number 35,000
Market value in DKK 82,700
Name AntiAnthra ApS, a company owned by CED of TopoTarget A/S,
Reason Peter Buhl Jensen, Chief Scientific Officer Maxwell
Sehested and a third party
Issuer TopoTarget A/S
ISIN DK0060183515
Transaction Sale of subscription rights
Trade date 24 June 2009
Market NASDAQ OMX Copenhagen A/S
Number 1,295,000 subscription rights
Market value in DKK 85,302
It is noted that the transactions mentioned above are unrelated to the
subscription undertaking made by CEO Peter Buhl Jensen to subscribe - through
Buhl Krone Holding ApS - 239,222 offer shares as part of TopoTarget A/S'
current rights issue of shares.
TopoTarget A/S
For further information, please contact:
Peter Buhl Jensen Telephone +45 39 17 94 99
CEO Mobile +45 21 60 89 22
Background information
About TopoTarget
TopoTarget (OMX: TOPO) is an international biotech company headquartered in
Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. The company was founded and is run by clinical cancer
specialists and combines years of hands-on clinical experience with in-depth
understanding of the molecular mechanisms of cancer.
TopoTarget has a broad clinical pipeline but is currently focusing on the
development of belinostat, which has shown proof of concept as monotherapy in
treating haematological malignancies and positive results in solid tumours
where it can be used in combination with full doses of chemotherapy, and is in
phase III in PTCL. TopoTarget's expertise in translational research is
utilizing its highly predictive in vivo and in vitro cancer models. TopoTarget
is directing its efforts on key cancer targets including HDACi, NAD+, mTOR,
FasLigand and topoisomerase II inhibitors. The company's first marketed product
Savene®/Totect® was approved by EMEA in 2006 and the FDA in 2007 and is
marketed by TopoTarget's own sales force in Europe and the US. For more
information, please refer to www.topotarget.com.
